Assertio Holdings

Historical price data

Assertio Holdings is a NASDAQ-listed commercial biotech focused on acquiring and maximizing established pharmaceutical products in neurology, pain management, and hospital care. Its strategy centers on a lean commercial model, targeting non-promoted or under-valued brands for strategic marketing and lifecycle extensions. Recent years have seen significant corporate transformation, including portfolio divestitures and a name change, to sharpen focus on its core therapeutic areas and return to profitability.

A commercial and strategic asset management platform focused on identifying, acquiring, and maximizing the value of established pharmaceutical products through regulatory lifecycle management and targeted commercialization.

Assertio faces intense, product-specific competition. ROLVEDON competes with entrenched G-CSF therapies like Neulasta, INDOCIN holds a niche in neonatal care, and products like Otrexup and SYMJEPI operate in crowded generic and branded markets, requiring targeted promotion to maintain share.